Why Is Women Health-Focused Organon Stock Trading Higher On Thursday?



Thursday, Organon & Co (NYSE:OGN) reported an 8% Y/Y increase in the fourth quarter of 2023, reaching around $1.6 billion, beating the consensus of $1.55 billion.

Women’s Health revenue increased by 7% as reported and 8% ex-FX, driven by strong growth in fertility products, particularly Follistim AQ. 

Follistim grew 63% ex-FX due to increased demand in the U.S. that was largely tied to onboarding a new customer, and volume recovery in China …

Full story available on Benzinga.com


Leave a Reply

Your email address will not be published. Required fields are marked *